Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Tiziana Life Sciences LtdNASDAQ: TLSA

Weighted Avg Shares · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares grows 9.0% year over year

Q4 FY2025 weighted avg shares of 59.47M shares rose 9.0% year over year. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
59.47M— QoQ
Last fiscal yearDec 2025
59.14M+10.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.0%——
1 year+10.9%——
3-year CAGR+5.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
59.14M USD
Year-over-year change
+10.9%
4-year CAGR
+4.8%

Weighted Avg Shares vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 weighted avg shares of 59.14M shares is the 5th highest of the 9 companies compared; the peer median is 50.49M shares.
  • Its year-over-year change of +10.9% is the 4th highest of 9, against a peer median of +4.2%.
  • Over three fiscal years its annual growth of +5.2% compares with a peer median of +16.2%.
TLSA Competitors Peer median
Weighted Avg Shares for TLSA and competitors
Company Period LTM YoY 3-year CAGR
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202668.95M +154.8%+40.1%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
TLSATiziana Life Sciences LtdFY202559.14M +10.9%+5.2%
OKYOOKYO Pharma LimitedFY202539.49M +34.6%+37.9%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
EXOZeXoZymes, Inc.LTM Mar 20268.4M +2.6%+1.0%
Peer median (excluding TLSA) 50.49M+4.2%+16.2%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000234K
Gross Profit0000(234K)
Gross Margin—————
Research & Development17.82M15.92M10.25M5.23M10.28M
Selling, General & Admin1.15M4.76M8.26M10.28M10.77M
Operating Expenses36.93M17.93M22.73M15.79M21.05M
Depreciation & Amortization190.2K62.68K121.34K124K234K
EBITDA(35.53M)(18.85M)(21.66M)(16.62M)(21.05M)
EBITDA Margin—————
Operating Income(36.93M)(17.93M)(22.73M)(15.79M)(21.28M)
Operating Margin—————
Interest Income001.46M814K19K
Interest Expense237.41K8.6K12.64K6K18K
Other Income / Expenses967.18K(996.78K)937.89K(952K)2.85M
Income Before Tax(35.96M)(18.92M)(21.79M)(16.75M)(18.43M)
Pre-Tax Margin—————
Income Tax Expense(4.37M)0567.54K(4.88M)0
Net Income(31.59M)(18.92M)(22.36M)(11.86M)(18.43M)
Net Margin—————
EPS (Basic)(0.64)(0.36)(0.42)(0.22)(0.32)
EPS (Diluted)(0.64)(0.36)(0.42)(0.22)(0.32)
Weighted Avg Shares48.97M50.76M50.76M53.34M59.14M
Weighted Avg Shares (Diluted)48.97M50.76M50.76M53.34M59.14M

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.